

Bod Science Webinar Invitation Investor Presentation

Sydney, Australia – 12 July 2023: Cannabis focused drug development and product innovation company Bod Science Limited (“Bod” or “the Company”) (ASX: BOD) is pleased to invite shareholders and investors to a webinar hosted by Chief Executive Officer, Jo Patterson, who will present Bod’s latest Investor Presentation, discussing near term value drivers, including completion of Aqua Phase comparing with CBD in oil, completion of Phase IIB study for Insomnia for TGA ARTG registration, expansion into the Malaysian market through collaboration with Antah Pharma and the expansion of Bod’s medical cannabis product portfolio.

Shareholders and investors are invited to register for the free webinar here:

Webinar URL: <https://attendee.gotowebinar.com/register/1563748959144869209>

Date: Thursday, 13 July 2023

Time: 09:30am AWST (Perth) / 11:30am AEST (Sydney/Melbourne)

After registering, you will receive a confirmation email with a calendar invitation and information about joining the webinar.

The format of the webinar will be a 15-minute presentation, followed by a live Q&A. Investors are encouraged to submit questions prior to the webinar.

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033